TherapeuticsMD has been growing earnings at an average annual rate of 74.4%, while the Pharmaceuticals industry saw earnings growing at 8.5% annually. Revenues have been declining at an average rate of 32% per year. TherapeuticsMD's return on equity is 0.3%, and it has net margins of 2.6%.
Key information
74.42%
Earnings growth rate
80.64%
EPS growth rate
Pharmaceuticals Industry Growth
7.33%
Revenue growth rate
-31.99%
Return on equity
0.32%
Net Margin
2.56%
Last Earnings Update
31 Mar 2026
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How TherapeuticsMD makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
BST:29TA Revenue, expenses and earnings (USD Millions)
Date
Revenue
Earnings
G+A Expenses
R&D Expenses
31 Mar 26
3
0
5
0
31 Dec 25
3
-1
5
0
30 Sep 25
3
0
4
0
30 Jun 25
3
-1
4
0
31 Mar 25
2
-2
5
0
31 Dec 24
2
-2
5
0
30 Sep 24
2
-4
5
0
30 Jun 24
1
-5
6
0
31 Mar 24
1
-6
7
0
31 Dec 23
1
-8
9
0
30 Sep 23
69
42
18
0
30 Jun 23
70
29
30
0
31 Mar 23
70
17
42
0
31 Dec 22
70
1
57
0
30 Sep 22
-64
3
-26
-6
30 Jun 22
-39
-30
10
-4
31 Mar 22
-17
-58
48
-2
31 Dec 21
3
-79
73
0
30 Sep 21
91
-172
194
8
30 Jun 21
85
-157
182
8
31 Mar 21
72
-166
178
9
31 Dec 20
65
-184
193
10
30 Sep 20
58
-191
198
12
30 Jun 20
63
-190
204
15
31 Mar 20
58
-193
196
17
31 Dec 19
50
-176
175
20
30 Sep 19
39
-166
157
22
30 Jun 19
19
-170
142
25
31 Mar 19
16
-148
130
27
31 Dec 18
16
-133
116
27
30 Sep 18
15
-115
95
32
30 Jun 18
16
-94
76
31
31 Mar 18
17
-80
62
33
31 Dec 17
17
-77
58
34
30 Sep 17
17
-78
60
33
30 Jun 17
18
-89
63
41
31 Mar 17
18
-90
59
47
31 Dec 16
19
-90
51
54
30 Sep 16
20
-85
44
57
30 Jun 16
20
-79
36
59
31 Mar 16
21
-85
32
69
31 Dec 15
20
-85
29
72
30 Sep 15
19
-84
26
73
30 Jun 15
18
-82
25
71
Quality Earnings: 29TA has a large one-off loss of $88.0K impacting its last 12 months of financial results to 31st March, 2026.
Growing Profit Margin: 29TA became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 29TA has become profitable over the past 5 years, growing earnings by 74.4% per year.
Accelerating Growth: 29TA has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: 29TA has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (15.1%).
Return on Equity
High ROE: 29TA's Return on Equity (0.3%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
7D
1Y
7D
1Y
7D
1Y
Company Analysis and Financial Data Status
Data
Last Updated (UTC time)
Company Analysis
2026/06/28 09:49
End of Day Share Price
2026/06/26 00:00
Earnings
2026/03/31
Annual Earnings
2025/12/31
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
TherapeuticsMD, Inc. is covered by 17 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.